Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease
Identifieur interne : 000B43 ( Main/Exploration ); précédent : 000B42; suivant : 000B44Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease
Auteurs : A H Evans [Australie, Royaume-Uni] ; A D Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Source :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2009-03.
Abstract
Background: Sustained drug therapy in Parkinson’s disease may alter the psychomotor responses to acute challenges with dopaminergic drugs, L-dopa and methylphenidate, and cause cross sensitisation. Methods: The mood, psychomotor and reward potentiating effects of an acute challenge with L-dopa and methylphenidate on separate occasions were assessed under double blind (medication naïve) conditions after a placebo and then the testing sessions were repeated in the same (medication experienced) patients following a median period of 16.7 months of continuous dopaminergic drug therapy. Results: In the medication naïve condition, affect was not changed by L-dopa or methylphenidate and only L-dopa improved motor function. In the medication experienced condition, active drugs improved positive affect compared with the medication naïve condition and there was an enhanced effect of L-dopa on motor function. Reward responsivity was enhanced by both L-dopa and methylphenidate in medication naïve and experienced conditions. Conclusion: Sustained dopaminergic drug therapy augments the motor effects of an acute challenge with L-dopa and induces euphoriant effects to L-dopa and methylphenidate challenges.
Url:
DOI: 10.1136/jnnp.2006.108993
Affiliations:
- Australie, Royaume-Uni
- Angleterre, Grand Londres
- Londres
- National Hospital for Neurology and Neurosurgery
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease</title><author><name sortKey="Evans, A H" sort="Evans, A H" uniqKey="Evans A" first="A H" last="Evans">A H Evans</name></author><author><name sortKey="Lawrence, A D" sort="Lawrence, A D" uniqKey="Lawrence A" first="A D" last="Lawrence">A D Lawrence</name></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">Andrew Lees (neurologue)</name><affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2BB0827695B620F50DCE4569A91140740336D6D0</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1136/jnnp.2006.108993</idno><idno type="url">https://api.istex.fr/document/2BB0827695B620F50DCE4569A91140740336D6D0/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001F83</idno><idno type="wicri:Area/Main/Curation">001C87</idno><idno type="wicri:Area/Main/Exploration">000B43</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease</title><author><name sortKey="Evans, A H" sort="Evans, A H" uniqKey="Evans A" first="A H" last="Evans">A H Evans</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Neurology, The Royal Melbourne Hospital, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Melbourne</wicri:regionArea><wicri:noRegion>University of Melbourne</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lawrence, A D" sort="Lawrence, A D" uniqKey="Lawrence A" first="A D" last="Lawrence">A D Lawrence</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University, Cardiff</wicri:regionArea><wicri:noRegion>Cardiff</wicri:noRegion></affiliation></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">Andrew Lees (neurologue)</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2009-03">2009-03</date><biblScope unit="volume">80</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="267">267</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">2BB0827695B620F50DCE4569A91140740336D6D0</idno><idno type="DOI">10.1136/jnnp.2006.108993</idno><idno type="href">jnnp-80-267.pdf</idno><idno type="ArticleID">jn108993</idno><idno type="PMID">18977820</idno><idno type="local">jnnp;80/3/267</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background: Sustained drug therapy in Parkinson’s disease may alter the psychomotor responses to acute challenges with dopaminergic drugs, L-dopa and methylphenidate, and cause cross sensitisation. Methods: The mood, psychomotor and reward potentiating effects of an acute challenge with L-dopa and methylphenidate on separate occasions were assessed under double blind (medication naïve) conditions after a placebo and then the testing sessions were repeated in the same (medication experienced) patients following a median period of 16.7 months of continuous dopaminergic drug therapy. Results: In the medication naïve condition, affect was not changed by L-dopa or methylphenidate and only L-dopa improved motor function. In the medication experienced condition, active drugs improved positive affect compared with the medication naïve condition and there was an enhanced effect of L-dopa on motor function. Reward responsivity was enhanced by both L-dopa and methylphenidate in medication naïve and experienced conditions. Conclusion: Sustained dopaminergic drug therapy augments the motor effects of an acute challenge with L-dopa and induces euphoriant effects to L-dopa and methylphenidate challenges.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement><orgName><li>National Hospital for Neurology and Neurosurgery</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Evans, A H" sort="Evans, A H" uniqKey="Evans A" first="A H" last="Evans">A H Evans</name></noRegion><name sortKey="Evans, A H" sort="Evans, A H" uniqKey="Evans A" first="A H" last="Evans">A H Evans</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Evans, A H" sort="Evans, A H" uniqKey="Evans A" first="A H" last="Evans">A H Evans</name></region><name sortKey="Lawrence, A D" sort="Lawrence, A D" uniqKey="Lawrence A" first="A D" last="Lawrence">A D Lawrence</name><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">Andrew Lees (neurologue)</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2BB0827695B620F50DCE4569A91140740336D6D0
|texte= Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.23. |  |